Two Years After Category A: The VHP Adoption Landscape in 2026

In January 2024, the FDA formally reclassified vaporized hydrogen peroxide sterilization to Established Category A — placing VHP alongside steam, ethylene oxide, dry heat, and radiation as a recognized sterilization method with an established body of scientific evidence. Two years later, the practical consequences of that reclassification are visible across submission databases, contract sterilization pricing sheets, and device manufacturer capital plans in ways that were not predictable from the announcement alone.

This is not a summary of the announcement. It is an assessment of what has actually changed in the two years since.

What Category A Recognition Meant — and What It Has Produced

Before January 2024, VHP sterilization occupied FDA's Category B designation — a category for methods with a developing but not fully established evidence base. Category B submissions required manufacturers to provide justification that their VHP process was equivalent to or better than established methods, adding documentation burden and review uncertainty that Category A submissions do not carry.

FDA's January 2024 Category A reclassification changed the submission standard to: demonstrate a validated process using VHP, validated per ISO 22441:2022, achieving SAL 10⁻⁶. That is the same standard applied to EtO (ISO 11135), steam (ISO 17665), and irradiation (ISO 11137). The method justification step is gone. The evidentiary burden is the process validation package, not a case for the method itself.

In practice, this has produced measurable changes in submission behavior. VHP sterility sections in 510(k) submissions filed through 2024 and 2025 reflect the new standard: the method is cited by name with the Category A designation and the ISO 22441 standard reference, and the submission moves directly into validation documentation. FDA review correspondence on VHP method acceptability — a known source of review cycles under Category B — has effectively ceased for submissions that follow the ISO 22441 framework. For manufacturers who had been deferring VHP transitions because of regulatory uncertainty, Category A recognition removed the primary objection.

The ISO 22441 Standard Has Become Operational

ISO 22441:2022 was published in late 2022 and recognized by FDA as a consensus standard in May 2023 — seven months before the Category A reclassification. In the period immediately following both milestones, the standard was more widely referenced than practiced. Validation teams were still developing familiarity with its requirements. Biological indicator suppliers were calibrating their product offerings to the standard's specifications. Contract validation laboratories were building ISO 22441 service lines.

Two years later, the standard is operational. Validation teams that have executed ISO 22441-aligned IQ/OQ/PQ packages have published those experiences in regulatory submissions that are now part of FDA's review record. Contract validation laboratories at Nelson Labs, SGS, and Charles River Laboratories offer ISO 22441-aligned services as standard offerings. Biological indicator suppliers provide G. stearothermophilus products calibrated specifically to VHP exposure conditions with published D-values appropriate for half-cycle method PQ execution.

The structural implication: manufacturers beginning VHP validation now are not navigating an unfamiliar pathway. They have access to a mature service ecosystem — standard BIs, standard contract services, and a growing library of precedent submissions — that did not exist in early 2024. The validation timeline for a manufacturer starting today is faster and lower-risk than for the early movers who helped establish those precedents.

The Global Regulatory Convergence

The Category A reclassification was a U.S. regulatory event. Its practical implications have extended globally, through the mechanism of ISO 22441's status as an internationally harmonized standard.

In the European Union, ISO 22441:2022 provides the technical framework for VHP sterilization assessment under EU MDR 2017/745. Notified Bodies reviewing technical documentation for CE-marked devices sterilized with VHP reference ISO 22441 as the applicable standard — the same role ISO 11135 plays for EtO in EU submissions. For manufacturers with both FDA and EU commercial objectives, a single ISO 22441-aligned validation package now supports both regulatory pathways. The dual-jurisdiction efficiency that has always been available for EtO manufacturers (ISO 11135 accepted by both FDA and EU) is now available for VHP.

Health Canada references ISO sterilization standards through its medical device regulatory framework, extending the ISO 22441 pathway to Canadian submissions. TGA (Australia) and PMDA (Japan) similarly operate within ISO-harmonized frameworks. The practical result: a manufacturer with a globally commercialized device can build a single VHP validation architecture that supports regulatory submissions in the U.S., EU, Canada, Australia, and Japan without jurisdiction-specific sterilization method arguments.

Three Structural Shifts for Device Manufacturers

Beyond the regulatory pathway changes, two years of market operation under Category A have produced three structural shifts in the commercial and operational environment device manufacturers navigate.

**Regulatory conversations have shortened materially.** The change is not merely that FDA reviewers accept VHP — they accepted it before, under Category B. The change is that the conversation about whether VHP is appropriate for a given application has largely ended. Pre-submission meetings focused on sterilization now address process validation design, packaging compatibility, and residue assessment methodology rather than method justification. The predictability of the review process has increased substantially, which affects development planning timelines in ways that compound over multi-year device programs.

**Contract EtO sterilization costs have risen — structurally, not cyclically.** The EPA's April 2024 final rule requiring 90%+ reductions in EtO emissions from commercial sterilizers initiated a multi-year capital investment cycle at EtO facilities. Those investments — scrubbers, monitoring systems, abatement infrastructure — are being recovered through pricing. Industry reporting documents per-unit cost increases across the contract sterilization sector, with smaller-volume customers absorbing proportionally larger increases. The March 2026 EPA proposed reconsideration has paused some of the compliance urgency, but it has not reversed the capital investments already made or the pricing changes already implemented. EtO sterilization costs are higher than they were in 2023, and the structural forces maintaining that elevation have not been resolved.

**In-house sterilization capability has moved from capital project to strategic asset.** The supply chain disruptions of 2020–2023 made visible what was previously theoretical: manufacturers dependent on a single contract sterilizer for product release hold a structural vulnerability that cannot be managed reactively. Device manufacturers who have built in-house VHP capability in the two years since Category A recognition are not just responding to cost pressure — they are removing a critical single point of failure from their product release chain. The sterilization step governs every downstream activity: packaging, labeling, release testing, distribution. In-house control of that step is supply chain resilience in its most direct form.

The Second Wave: Who Is Moving Now

The first wave of VHP adoption — manufacturers with material sensitivities that precluded irradiation, or combination products that couldn't tolerate EtO residue — was driven by technical necessity as much as regulatory opportunity. These manufacturers had no viable alternative; Category A recognition cleared their submission pathway but did not change their fundamental technology decision.

The second wave is different in character. It includes manufacturers for whom EtO or irradiation was technically adequate but is now economically or operationally suboptimal. It includes manufacturers whose products are temperature-sensitive and who have calculated the cold chain cost of shipping refrigerated product to an irradiation facility against the capital cost of in-house VHP. It includes tissue banks that have recognized the custody and biological preservation arguments for in-house VHP. And it includes contract sterilizers who are adding VHP capability to serve the product categories their EtO operations cannot optimally handle.

The common thread is not regulatory pressure — it is a cost-benefit analysis that has shifted. Two years of Category A recognition, ISO 22441 operationalization, and contract sterilization cost escalation have moved the economics in ways that make in-house VHP the rational choice for a broader set of manufacturers than it was in January 2024.

What Has Not Changed

Category A is a regulatory designation. It is not a technical simplification. Manufacturers implementing VHP sterilization still execute the full IQ/OQ/PQ validation lifecycle under ISO 22441 — process development, material compatibility assessment, chamber mapping, biological indicator qualification, and performance qualification with three consecutive successful runs. SAL 10⁻⁶ must still be demonstrated. Residue assessment is still required under ISO 22441 Section 5.4.5. Ongoing monitoring — biological indicator testing, parametric release, periodic requalification — is still required as a condition of maintaining a validated process.

Category A means the regulatory conversation about whether VHP is an acceptable method has ended. It does not mean the validation work required to demonstrate that a specific process achieves sterility has been reduced. Manufacturers who approach VHP implementation expecting a regulatory shortcut will encounter the same validation rigor that Category A has always required of established methods.

The manufacturers who are succeeding with VHP implementation are those who understand both dimensions: the regulatory pathway is now clear and efficient, and the validation execution must be rigorous and complete. Those two facts are not in tension. They are complementary properties of a well-designed sterilization program.

Frequently Asked Questions

**What did FDA's Category A reclassification actually change for a 510(k) submission?**

Before Category A, VHP sterilization required manufacturers to include justification that VHP was equivalent to or better than established methods — an additional documentation burden that introduced review uncertainty and extended timelines. After Category A reclassification in January 2024, the sterility section of a 510(k) presents VHP as an established method (citing Category A status and ISO 22441:2022) and proceeds directly to process validation documentation — IQ/OQ/PQ, biological indicator data, material compatibility, and residue assessment. The method justification step has been eliminated. The evidentiary standard is the same as for EtO, steam, or radiation.

**Does ISO 22441 support regulatory submissions outside the United States?**

Yes. ISO 22441:2022 is an internationally harmonized standard recognized by regulatory authorities that reference ISO standards for medical device sterilization assessment. In the European Union, ISO 22441 supports VHP sterilization assessment under EU MDR 2017/745. Health Canada, TGA (Australia), and PMDA (Japan) operate within ISO-harmonized frameworks. A single ISO 22441-aligned VHP validation architecture supports regulatory submissions in multiple jurisdictions — providing the same multi-market efficiency that EtO manufacturers have long accessed through ISO 11135.

**Has the EPA's March 2026 reconsideration of EtO emission rules changed the business case for VHP?**

The proposed reconsideration would relax certain emission reduction requirements, but it has not reversed the capital investments already made by EtO facilities in abatement infrastructure, nor has it eliminated the per-unit cost increases those investments produced. The underlying carcinogen classification of EtO is unchanged. Community opposition to EtO facility permitting in multiple U.S. states continues. The occupational exposure liability has not been resolved. Manufacturers who evaluate the EtO cost and risk environment solely through the lens of the 2026 reconsideration are looking at a temporary deceleration of regulatory pressure, not a return to the pre-2024 environment.

**What is the realistic timeline from Category A recognition to a validated VHP process?**

For a manufacturer beginning in 2026 with an existing process validation team and a single device product, 6–12 months from equipment procurement to a validated, submission-ready process is realistic. Process development and material compatibility assessment run in parallel with equipment installation and IQ; OQ and PQ follow sequentially. Manufacturers with more complex product portfolios or without prior sterilization validation experience will extend toward the upper end of that range or beyond. The timeline is driven by validation rigor, not regulatory complexity — Category A recognition did not shorten the IQ/OQ/PQ lifecycle.

**What does VHP adoption look like for tissue banks specifically?**

Tissue banks face a different adoption profile than device manufacturers. The regulatory framework for tissue sterilization is FDA CGTP (21 CFR Part 1271) and AATB Standards rather than 510(k)/PMA, but the technical requirements for VHP validation — process development, IQ/OQ/PQ, biological indicator qualification, residue assessment — are structurally equivalent. The institutional case for tissue banks is anchored in biological preservation (VHP does not generate the hydroxyl free radicals that damage collagen and denature growth factors during gamma irradiation) and custody control (in-house sterilization eliminates the custody break of shipping product to a third-party irradiator). For a detailed treatment of the tissue bank case, see [Why Irradiation Sterilizes the Biology Out of Your Allograft](/insights/irradiation-allograft-biological-damage) and [Complete Custody and Control](/insights/tissue-bank-sterilization-custody-control).